If plasma DNA sequencing alone is used, CH and mosaicism can lead to misinterpretation of mutations as tumor derived and might lead to trial enrollment on the basis of an alteration not present in the clinically relevant tumor (Heitzer et al. 2019, Köhnke & Majeti 2021, Serrano et al. 2020). This evidence concerns the gene C4B and neoplasm.